Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Ischemic preconditioning reduces infarct size in patients treated with primary angioplasty

Original title: Preinfarction Angina Reduces Infarct Size in ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention Reference: Ronald Reiter et al. Circ Cardiovasc Interv. 2013;6:00-00.

Ischemic preconditioning (IPC) is a phenomenon whereby transitory ischemia episodes protect the myocardium against a more prolonged episode. 

Until now, IPC has been the most effective approach to protect the myocardium. Pre infarction angina is a clinical surrogate of IPC and has been associated with reduced infarct size in patients that receive thrombolytic therapy; however this is not conclusive for patients treated with primary angioplasty.

245 patients with ST elevation myocardial infarction treated with primary angioplasty were analyzed; 79 of these patients had presented angina 24 hours before admition vs. 166 patients without pre infarction angina. There were no significant differences in the rest of baseline characteristics between both groups.

For the patients with previous angina, both infarct size and troponin peak was significantly reduced (p<0,0001) despite having identical ischemic times and angiographic results. Ejection Fraction was 4$ lower in patients with preconditioning (51,4±1,1% vs. 47,5±1%; p=0,02).

Conclusion 

This study is the most detailed analysis carried out so far on the potential protective effect of ischemic preconditioning in patients with ST elevation myocardial infarction treated with primary angioplasty.

Editorial Comment

Randomized studies on ST elevation acute coronary syndromes should start considering pre infarction angina among key variables, seeing that this could be an important confounder, mainly if infarct size is one of the primary concerns. A good example of this is the large number of trials assessing the use of thrombi aspiration.

SOLACI.ORG

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...